KSP
VC Fund
Kawasaki, Japan
KSP is a VC fund in Kawasaki focused on Biotechnology and Health Care. KSP, Inc. is the core business entity responsible for operating the Kanagawa Science Park (KSP) and has accepted the challenge of creating new industries through the support, development, and incubation of venture businesses. We provide a variety of business support services that best meet the needs of venture businesses in each stage of theirbusiness growth, ranging from the processes of startup and growth to public offerings. Several hundreds of new startup companies have been created and nurtured since its foundation. An incubation manager (IM) acts as a coordinator and provides a variety of support services to a venture company to help them successfully launch and develop their new business, such as offering individual consultations and a variety of information or advice. KSP, Inc. is well poised to cope with the varying needs of new ventures for highly sophisticated, specialized tasks by offering a business school, business support center, business matching services, and investment funds.The public sector, such as the Kanagawa prefectural government, Kawasaki city government, and the Development Bank of Japan, Inc., has an equity participation in KSP, thus playing a vital role in the deployment of local industrial development policy.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 6%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries KSP invests in
Stages KSP invests in
Countries KSP invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Biotechnology 13 (28%)
- Health Care 12 (26%)
- Medical 11 (23%)
- Manufacturing 8 (17%)
- Pharmaceutical 6 (13%)
Stage
- Funding Round 16 (34%)
- Series A 14 (30%)
- Seed 4 (9%)
- Series B 3 (6%)
- Series C 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kiichi Kubota
President
|
President | Total investments: 0 | Find email | |
|
Tomohiro Otsuki
Incubation Manager
|
Incubation Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scohia Pharma
|
Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M / May 28, 2026 | |
Anaut
|
Anaut specializes in software development utilizing artificial intelligence for surgical support in surgical medicine. | Series B / Mar 01, 2026 | |
3DC
|
3DC develops and manufactures a new carbon material, graphene meso sponge (GMS), for electrodes in next-generation batteries, capacitors, fuel cells and other energy storage and generation devices. | $16.7M / Series A / Aug 04, 2025 | |
A-SEEDS
|
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions. | $15M / Series A / Jul 07, 2025 | |
Nichietsu
|
Nichietsu is specializes in innovative molding solutions, offering products like mold changers and heavy duty transport vehicles. | $2.1M / Series A / Jun 10, 2025 | |
XFOREST Therapeutics
|
xFOREST Therapeutics develops a drug discovery platform that targets RNA structures. | $6.1M / Series A / Jan 24, 2025 | |
THE PHAGE
|
The phage is a medical device company that focuses on developing AI technology to predict postprandial blood glucose levels. | Seed / Sep 12, 2024 | |
|
3DC
|
3DC develops and manufactures a new carbon material, graphene meso sponge (GMS), for electrodes in next-generation batteries, capacitors, fuel cells and other energy storage and generation devices. | $3.7M / Seed / Jun 06, 2024 | |
ARUM
|
ARUM is a manufacturing AI software that can cut fifty percent of the cost structure in the metal and machine processing industry. | $4.9M / Series A / May 20, 2024 | |
Luxonus
|
Luxonus is a product development of a new imaging device using optical ultrasonic technology. | $1.6M / Series C / Jul 31, 2023 | |
| See all 47 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does KSP invest in?
KSP invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 47 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact KSP?
Public channels for KSP include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at KSP?
The team at KSP includes Kiichi Kubota (President) and Tomohiro Otsuki (Incubation Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
